First fully recyclable tubes with high-density polyethylene caps developed
Polyethylene-based tubes with high-density polyethylene flip-top caps that are fully recyclable have been developed for use in pharma.
List view / Grid view
News
First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
Chemspec Digital 2020: pave the way for the recovery of the fine and speciality chemicals industry
Hosted online from 11 – 12 November, Chemspec Digital 2020 provides an interactive networking event for the fine and speciality chemicals community. From all over the world, industry experts will have the opportunity to meet, conduct business, discover innovative substances and learn about the latest trends and developments.
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
FDA approves remdesivir for treatment of COVID-19
The FDA has given marketing authorisation for Veklury (remdesivir) to treat COVID-19 patients requiring hospitalisation.
Aspirin could protect patients from severe COVID-19 complications
A study has shown that aspirin use was associated with a 47 percent decrease in the risk of dying in the hospital from COVID-19.
Nanoformed formulation of piroxicam to enter Phase I trials
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
Nasal drug delivery technology market to grow at CAGR of 5.1 percent
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.
EMA recommends 10 medicines for approval in October meeting
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
EIB to support COVID-19 therapy with €24.5 million investment
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
UK to establish human challenge studies for COVID-19 vaccines
The UK government hopes to expedite the development of a COVID-19 vaccine by investing £33.6 million in the first phase of establishing human challenge trials.
Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials
Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.
Repurposed drugs not effective treatment for hospitalised COVID-19 patients, WHO says
WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
COVID-19 pandemic to heighten sales of pharmaceutical spray drying
A new report has predicted that the COVID-19 pandemic will drive demand for pharmaceutical spray drying, boosting the market.
Study suggests dolutegravir is the optimal first-line HIV medication
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
